共查询到20条相似文献,搜索用时 31 毫秒
1.
2.
3.
4.
Beom Jae Lee MD PhD Jong-Jae Park MD PhD Moon Kyung Joo MD Ji Hoon Kim MD PhD Jong Eun Yeon MD PhD Jae Seon Kim MD PhD Hoon Jai Chun MD PhD Kwan Soo Byun MD PhD Jae Hyun Choi MD PhD Chang Duck Kim MD PhD Young-Tae Bak MD PhD You-Jin Jang MD Young-Jae Mok MD PhD 《Gastrointestinal endoscopy》2010,71(7):1329-1332
5.
6.
7.
8.
9.
10.
11.
William A. Stack David Jenkins Philippe Vivet Christopher J. Hawkey for the Platelet Activating Factor Antagonist Study Group in Ulcerative Colitis 《Gastroenterology》1998,115(6):1340-1345
Background & Aims: Platelet-activating factor (PAF) is increased during relapse of ulcerative colitis. In animal models of experimental colitis, specific inhibition of PAF has reduced inflammation. The aim of this study was to evaluate the efficacy and safety of the PAF antagonist SR27417A in moderately active UC. Methods: A double-blind multicenter trial was conducted during a 28-day period in hospital outpatients with an exacerbation of ulcerative colitis. Patients were randomized to receive 10 mg/day SR27417A or placebo, and both groups were also given 2.4 g mesalazine. Patient classification at the end of the treatment period was based on sigmoidoscopy and clinical scores. Results: One hundred fifty-one subjects entered the study (75 placebo and 76 SR27417A). The remission rate between placebo- and SR27417A-treated patients at 28 days was not significantly different (29.0% and 35.6% respectively; P = 0.44). Similarly, 49.2% treated with SR27417A had a definite or possible improvement of their symptom score compared with 48.3% of those treated with placebo (P = 0.43). Four subjects in the placebo group and 5 subjects in the SR27417A group discontinued the drug treatment because of adverse events. No significant adverse events were thought to be caused by SR27417A. Conclusions: Although the specific PAF antagonist SR27417A is safe in humans, there is no evidence of efficacy in the treatment of acute ulcerative colitis.GASTROENTEROLOGY 1998;115:1340-1345 相似文献
12.
13.
14.
15.
16.
17.
18.
19.